PATENT CLAIM ANALYSIS

Application Number: 15986992
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-09
Patent Classification: ["424", "009100"]

Abstract:
S1P receptor modulators are administered following a dosage regimen providing a positive benefit-risk profile.

Claim (Index 33):
A method for treating multiple sclerosis in a patient in need thereof, comprising administering a drug selected from fingolimod and a pharmaceutically acceptable salt thereof, to said patient at a daily dosage of 0.5 mg, and wherein prior to administering said patient has been tested for history of chickenpox and the searched serology has been negative and said patient has been vaccinated against varicella zoster virus.

Metadata:
- Claim Count in Document: 101.0
- Percentile: 93.0
- Lexical Diversity: 1.07143
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['12655049', '14973105', '15418572', '13985342', '13149468']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6701959358454441
- 35 USC 102 Novelty (BERT): 0.5077180993514766
- Combined Prediction Score: 0.6539481521960474
- Mean Citation Score: 219.731472
- Max Citation Score: 239.65294
- Similarity Product: 163.24567555692434

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test